YuviwelWhat to know
30-second read
For Pediatrics · Orthopedic Surgery
- Who
- Children 2 and older with achondroplasia and open growth plates — already treatable in the U.S.; EU patients still await a final decision.
- What’s new
- The EMA’s CHMP recommended EU approval of once-weekly navepegritide (Yuviwel), only the second approved achondroplasia therapy worldwide.
- Evidence
- ApproaCH trial: 84 children randomized 2:1; week-52 annualized growth velocity 5.89 cm on navepegritide vs. 4.41 cm on placebo.
- Big advantage
- One subcutaneous injection a week instead of Voxzogo’s daily dose — though no head-to-head trial has tested the clinical difference that makes.
- Key consideration
- U.S. approval is accelerated, resting on a growth-velocity surrogate; a confirmatory trial still has to show the benefit holds for height, mobility or complications.
- Availability
- U.S. available since April 2026 (∼$37,400 WAC per 4-dose carton); EU decision expected Q4 2026, first launch planned in Germany, Q1 2027.
Practice impactConsider for new starts
A genuine second option, not yet a proven better one. Patients stable on Voxzogo have no evidence-based reason to switch; the weekly schedule mainly helps families starting therapy who are weighing whether daily injections are sustainable.
The EMA’s Committee for Medicinal Products for Human Use recommended EU marketing authorization for Ascendis Pharma’s once-weekly navepegritide, sold as Yuviwel, at its 12–15 October 2026 meeting — eight months after the same drug won U.S. accelerated approval. For physicians who treat achondroplasia, the opinion means a second drug is now close to matching BioMarin’s eight-year-old Voxzogo across both major regulatory regions. What it does not yet mean is that the newer drug is the better one.
A Second Drug for a One-Drug Disease
Achondroplasia, the most common form of short-limbed dwarfism, had exactly one approved drug from 2021 until February 2026: BioMarin’s vosoritide (Voxzogo), a daily-injected C-type natriuretic peptide (CNP) analog now sold in 55 countries. Navepegritide’s U.S. accelerated approval in February, and April launch, ended that monopoly in America. The CHMP’s 16 October opinion opens the same door in the EU, pending a European Commission decision the company expects by year-end and a first planned launch in Germany in early 2027. For a clinic that has only ever had one drug to prescribe or decline, this is the first time “which one” becomes a real question rather than a hypothetical.
What a Weekly Injection Changes in Practice
Both drugs work the same way: achondroplasia is caused by an FGFR3 mutation that keeps the growth-plate receptor permanently switched on, and CNP counteracts that signal. Natural CNP degrades within minutes, which is why Voxzogo is dosed daily. Navepegritide is built on Ascendis’s TransCon prodrug chemistry, designed to release CNP continuously from a single weekly subcutaneous injection rather than a daily peak and trough. For a family giving a young child an injection, 52 shots a year instead of 365 is a meaningful reduction in treatment burden — the kind of difference that shows up in adherence, not necessarily in growth centimeters. Ascendis has not published a trial testing navepegritide against Voxzogo directly, so the dosing-convenience argument rests on the two drugs’ separate pharmacokinetic profiles, not a comparative growth outcome.
What ApproaCH Did — and Didn’t — Prove
The approval rests on the pivotal ApproaCH trial: 84 children aged 2 to 11 with genetically confirmed achondroplasia, naive to growth-promoting therapy, randomized 2:1 to once-weekly navepegritide (57 patients) or placebo (27 patients) for 52 weeks, with up to three years of open-label extension data submitted alongside it. At week 52, annualized growth velocity reached 5.89 cm on navepegritide versus 4.41 cm on placebo — the superiority result both FDA and CHMP relied on.
ApproaCH at a glance
From the FDA approval notice and Yuviwel prescribing information. Growth velocity is a surrogate endpoint, not a measure of adult height or functional outcome.
What the trial did not test is anything downstream of growth velocity. Both FDA and CHMP based their decisions on this surrogate; the FDA’s accelerated-approval pathway now requires a confirmatory trial to verify the result translates into a longer-term clinical benefit — adult height, mobility, spinal or limb complications, or quality of life — the questions a family actually wants answered. That confirmatory obligation sits alongside, not instead of, the EU authorization process now underway.
Two CNP therapies for achondroplasia
| Yuviwel (navepegritide) | Voxzogo (vosoritide) | |
|---|---|---|
| Mechanism | TransCon CNP prodrug, designed for continuous release | CNP analog, direct daily exposure |
| Dosing | Once weekly, subcutaneous, weight-banded | Once daily, subcutaneous |
| Approved age / eligibility | 2 years and older, open growth plates | Open growth plates (U.S. label expanded from an initial 5-and-older floor) |
| Evidence basis | ApproaCH: 84 children, growth-velocity surrogate, accelerated approval | Phase 3 registration trial; approved 2021, longer real-world experience |
| Notable safety signal | Hypotension warning on label; no symptomatic hypotension reported in trials | Symptomatic hypotension reported in about 2% of treated patients in its phase 3 trial |
| Regulatory status | U.S. accelerated approval (Feb 2026); EU: CHMP positive opinion (Oct 2026), EC decision pending | Approved in the U.S. since 2021 and in 55 countries |
Each drug’s figures come from its own label and trials, not a head-to-head comparison. Navepegritide has not been tested directly against vosoritide; cross-trial safety comparisons should be read with that caveat.
Managing the Safety Profile in Clinic
Navepegritide carries no contraindications on its U.S. label. Adverse reactions in at least 5% of patients were vomiting, injection-site reaction, pain in the extremities and nausea. The label carries a hypotension warning shared across CNP therapies as a class, instructing families to contact their clinician for dizziness, lightheadedness, fainting or blurred vision rather than prescribing routine blood-pressure monitoring; in the phase 2b trial, asymptomatic hypotension occurred in a similar small share of patients on drug and on placebo, and none was judged treatment-related. The drug is not recommended for patients with moderate or severe renal impairment (eGFR under 60 mL/min/1.73m²). Dosing is weight-banded and given by prefilled, single-dose vial requiring reconstitution; the label calls for periodic reassessment of dose against weight and for stopping once epiphyseal closure ends growth potential.
Who Qualifies, and the Counseling Conversation
- Eligibility. Genetically confirmed achondroplasia, age 2 or older, with growth plates still open — the same population Voxzogo already covers.
- Naive vs. switching patients. The trial enrolled children naive to growth-promoting therapy; there is no comparative evidence for switching a patient already established on Voxzogo.
- Set expectations on the endpoint. Families should understand the approval rests on annualized growth velocity, a surrogate, not yet on a demonstrated change in adult height, mobility or complication rates.
- Weigh burden against evidence. A weekly injection is a genuine quality-of-life argument for families struggling with a daily regimen; it is not yet an efficacy or safety argument over the incumbent.
- Plan for an endpoint. Discontinuation follows growth-plate closure in either drug — this is not an indefinite therapy.
Availability on Both Sides of the Atlantic
In the U.S., Yuviwel has been commercially available since April 2026 at a wholesale acquisition cost of roughly $37,400 for a four-dose carton of the lowest (1.3 mg) strength; actual annual cost depends on a patient’s weight-banded dose. Several commercial and state Medicaid plans already carry prior-authorization criteria for the drug, but coverage is not yet universal, and Ascendis’s Signature Access Program offers a patient access liaison plus help with prior authorizations and appeals for prescribers. In the EU, reimbursement has not started: a CHMP positive opinion is a recommendation, not an authorization, and the European Commission’s decision — expected in the fourth quarter of 2026 — only grants marketing authorization. Price and coverage in each EU member state follow afterward, on that country’s own timeline, and nothing about them is yet settled.
For now, this is an approval that widens the choice, not one that resolves it. Pediatricians, geneticists and pediatric orthopedists treating achondroplasia should expect to field a dosing-frequency question from informed families well before either regulator or company answers the comparative-evidence question underneath it.
Sources & further reading
- FDA, “FDA Approves Drug for Pediatric Patients With the Most Common Form of Dwarfism,” 27 February 2026. fda.gov
- YUVIWEL (navepegritide) for injection, U.S. prescribing information, application 219164 — Dosage and Administration, Warnings and Precautions, Adverse Reactions. accessdata.fda.gov
- Ascendis Pharma, “Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children,” press release, 16 October 2026. globenewswire.com
- Regulatory News, “Ascendis Wins CHMP Backing for Achondroplasia Drug Yuviwel,” 17 October 2026 — the company and market account of this same CHMP opinion. regulatorynews.com
Regulatory News reports on public regulatory documents. It is not medical or legal advice, and the primary sources above govern. If we have made an error, we will say so in public: see corrections.
Frequently asked questions
Should a patient already stable on Voxzogo switch to Yuviwel?
There is no evidence basis for switching a patient doing well. Ascendis has not run a trial comparing navepegritide against vosoritide, so the weekly-versus-daily difference rests on separate pharmacokinetic profiles, not a head-to-head growth result. Switching is reasonable to discuss only where the daily injection itself is the barrier to adherence — not as a presumed upgrade.
What monitoring does Yuviwel need beyond growth measurements?
The label does not call for routine labs beyond periodic growth and weight-based dose review, with discontinuation once the growth plates close. Counsel families on symptoms of low blood pressure — dizziness, lightheadedness, fainting or blurred vision — reported as a class effect of CNP therapies, and avoid the drug in patients with moderate or severe renal impairment (eGFR under 60 mL/min/1.73m²).
Is Yuviwel reimbursed, in the U.S. or the EU?
In the U.S., several commercial and Medicaid plans already have prior-authorization criteria on file, but coverage is not universal and Ascendis's A.S.A.P. program assists with appeals and copay support. In the EU, reimbursement is separate from and follows the European Commission's marketing-authorization decision; individual member states set price and coverage on their own timelines, which have not yet started.
